Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone

Abstract Background To compare the response and safety of Ixazomib/Lenalidomide/Dexamethasone (IRd) and Bortezomib/Lenalidomide/Dexamethasone (VRd) treatment in newly diagnosed multiple myeloma (MM). Methods This was a single‐center retrospective analysis in Xiangtan Central Hospital. A total of 52...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhongjun Huo, Fang Chen, Ping Liu, Zimian Luo
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
adverse events
bortezomib
Ixazomib
newly diagnosed multiple myeloma
real world
Online Access:https://doi.org/10.1002/cam4.5198
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items